Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Brl-48482 SCHEMBL1850299 | 0.83 | PPARG (0.68) | PPARGPPARA | |
| Brl-48482 SCHEMBL6806392 | 0.82 | PPARG (0.67) | PPARGPPARA | |
| SCHEMBL1850303 | 0.82 | PPARG (0.58) | PPARGPPARA | |
| Water SCHEMBL6806396 | 0.81 | PPARG (0.57) | PPARGPPARA | |
| SCHEMBL9206600 | 0.80 | PPARG (0.55) | PPARGPPARA | |
| SCHEMBL24477260 | 0.79 | PPARG (0.66) | PPARGPPARA | |
| SCHEMBL29547010 | 0.79 | PPARG (0.66) | PPARGPPARA | |
| SCHEMBL12521892 | 0.79 | PPARG (0.58) | PPARGPPARA | |
| SCHEMBL7826285 | 0.79 | PPARG (0.68) | PPARGPPARA | |
| SCHEMBL1848402 | 0.79 | PPARG (0.62) | PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9682125-B2 | Compositions and methods for treating cognitive deficits | CASE WESTERN RESERVE UNIVERSITY (US) | 2017-06-20 | — | — | US | claimed |
| US-9421197-B2 | Methods of generating hyper INOS expressing cells and uses thereof | CASE WESTERN RESERVE UNIVERSITY (US) | 2016-08-23 | — | — | US | claimed |
| US-20140364461-A1 | METHOD OF TREATING DERMATOLOGICAL DISORDERS | UNIV CASE WESTERN RESERVE (US) | 2014-12-11 | — | — | US | claimed |
| US-20140335105-A1 | METHODS OF GENERATING HYPER INOS EXPRESSING CELLS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-11-13 | — | — | US | claimed |
| US-20140235676-A1 | RXR AGONIST COMPOUNDS AND METHODS | UNIV CASE WESTERN RESERVE (US) | 2014-08-21 | — | — | US | claimed |
| EP-2766018-A2 | RXR AGONISTS COMPOUNDS AND METHODS | Case Western Reserve University (US) | 2014-08-20 | — | — | EP | claimed |
| US-8796282-B2 | Method of treating dermatological disorders | CASE WESTERN RESERVE UNIVERSITY (US) | 2014-08-05 | — | — | US | claimed |
| US-8790925-B2 | Methods of generating hyper iNOS expressing cells and uses thereof | CASE WESTERN RESERVE UNIVERSITY (US) | 2014-07-29 | — | — | US | claimed |
| US-20140170165-A1 | METHODS OF GENERATING HYPER INOS EXPRESSING CELLS AND USES THEREOF | CASE WESTERN RESERVE UNIVERSITY (US) | 2014-06-19 | — | — | US | claimed |
| WO-2013056232-A2 | RXR AGONISTS COMPOUNDS AND METHODS | CASE WESTERN RESERVE UNIVERSITY (US) | 2013-04-18 | — | — | WO | claimed |
| US-6552055-B2 | Peroxidsome proliferator activated receptors | DANA-FARBER CANCER INSTITUTE | 2003-04-22 | — | — | US | claimed |
| US-20020106796-A1 | PAX8-PPARgamma nucleic acid molecules and polypeptides and uses thereof | BRIGHAM AND WOMEN'S HOSPITAL, INC., THE | 2002-08-08 | — | — | US | claimed |
| EP-1143953-A3 | METHOD OF INHIBITING ANGIOGENESIS | Genentech, Inc. (US) | 2002-02-06 | — | — | EP | claimed |
| US-20010036955-A1 | Method of inhibiting angiogenesis | GENENTECH, INC. | 2001-11-01 | — | — | US | claimed |
| EP-1143953-A2 | METHOD OF INHIBITING ANGIOGENESIS | Genentech, Inc. (US) | 2001-10-17 | — | — | EP | claimed |
| WO-2001052789-A2 | PAX8-PPARη NUCLEIC ACID MOLECULES AND POLYPEPTIDES AND USES THEREOF | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2001-07-26 | — | — | WO | claimed |
| US-6207690-B1 | TREATING TUMOR BY ADMINISTERING THERAPEUTICALLY EFFECTIVE AMOUNT OF TRIGLITAZONE COMPOUND | BOARD OF REGENTS, THE UNIVERSITY TEXAS SYSTEM | 2001-03-27 | — | — | US | claimed |
| WO-2000030628-A2 | METHOD OF INHIBITING ANGIOGENESIS | GENENTECH, INC. (US) | 2000-06-02 | — | — | WO | claimed |
| EP-0719140-A1 | USE OF THIAZOLIDINEDIONES TO PREVENT OR DELAY ONSET OF NIDDM | Sankyo Company Limited (JP) | 1996-07-03 | — | — | EP | claimed |
| WO-1995007694-A1 | USE OF THIAZOLIDINEDIONES TO PREVENT OR DELAY ONSET OF NIDDM | SANKYO COMPANY, LIMITED (JP) | 1995-03-23 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010036955-A1 | Method of inhibiting angiogenesis | PPARG, PPARA, RXRG | PPARG 1/4885PPARA 2/4885 |
| US-20140364461-A1 | METHOD OF TREATING DERMATOLOGICAL DISORDERS | PPARA, PPARG, PPARD | PPARG 2/4885PPARA 1/4885 |
| US-20140235676-A1 | RXR AGONIST COMPOUNDS AND METHODS | RXRA, RXRB, RXRG | PPARG 20/4885PPARA 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.